Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O43148

UPID:
MCES_HUMAN

ALTERNATIVE NAMES:
RG7MT1; mRNA (guanine-N(7))-methyltransferase; mRNA cap methyltransferase

ALTERNATIVE UPACC:
O43148; B0YJ90; D3DUJ5; O94996; Q9UIJ9

BACKGROUND:
The protein mRNA cap methyltransferase, with alternative names RG7MT1 and mRNA (guanine-N(7))-methyltransferase, is integral to mRNA stability and translation. By methylating the N7 position of the guanosine at the 5'-cap of mRNAs, it ensures the proper processing and function of mRNA, a fundamental step in gene expression.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of mRNA cap methyltransferase unveils potential therapeutic opportunities. Given its essential role in mRNA maturation and its impact on gene expression, targeting this protein could lead to novel treatments for conditions characterized by aberrant gene expression patterns.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.